Bacteriophages and their applications: general aspects and a new insight in Ethiopia
Bacteriophages, having a variety of function in different disciplines, are viruses that invade bacterial cells. Phages are enormously essential to the ecology and evolution of bacteria, and have huge impacts on global weather patterns. Due to their easiness to manipulate, they have been used in dissimilar types of genetic analysis and also implemented in hydrological tracing. Modified filamentous bacteriophages can be used in the production of nanodevices and as an agent in extraction of triacylglycerols. While their invention over a decade, they have been subjugated mainly to treat infections caused by bacteria. Phage therapy could become a welcome option in this era with a paucity of new antibiotic to battle against multi-drug resistant pathogens. This enemy of bacteria can also be used to combat antimicrobial resistance. This annotation is tried to touch the current progress in bacteriophage research and applications including biocontrols, diagnostic purposes, drug innovation and new drug delivery systems. Regarding efforts made in Ethiopia, there is limited study on isolation of phage and their therapeutic potential. Antibiotic resistance is of major community health concern in Ethiopia. Hence, the idea of using bacteriophage should be taken into consideration and health professionals should have to show inclination towards phage therapy. Moreover, substantial academic efforts have to be made before approval of phage utilization in Ethiopia.
2. Xavier wittebole, Sophie De Roock, Steven M Opal, A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens, Virulence, 2014; 5(1):226–235.
3. Pelzek AJ, Schuch R, Schmitz JE, Fischetti VA, Isolation, culture, and characterization of bacteriophages, Current Protocols Essential Laboratory Techniques, 2013; 4(4.4):4.4.1–4.4.33.
4. Ackermann HW, Prangishvili D, Prokaryote viruses studied by electron microscopy, Arch Virol, 2012; 157:1843-9.
5. Keen, Eric C., A century of phage research: Bacteriophages and the shaping of modern biology: Cause to reflect, BioEssays, 2015; 37(1):6–9.
6. Ipek Kurtböke, Bacteriophages. InTech; Janeza Trdine 9, 51000 Rijeka, Croatia, 2012, ISBN 978-953-51-0272-4. www.library.umac.mo.
7. KHANACADEMY, Bacteriophages. Bacteria-infecting viruses. The lytic and lysogenic cycles, 2018. www.khanacademy.org.
8. Stephen T. Abedon, Introduction to Bacteriophages, 2016. Phage-therapy.org.
9. Ada Hagan, Bacteriophage: A Drop In The Carbon Ocean. American Society for Microbiology, 2016. www.asm.org.
10. Regina Bailey, 7 Facts About Bacteriophages, 2018. www.biology.about.com.
11. Danovaro R, Corinaldesi C, dell’Anno A, Fuhrman J et al., Marine viruses and global climate change. FEMS Microbiol Rev., 2011; 35:993–1034.
12. Markus G. Weinbauer, Martin Agis, Osana Bonilla-Findji, Andrea Malits, Christian Winter, Bacteriophage: Genetics and Molecular Biology (Edited by: Stephen Mc Grath and Douwe van Sinderen). Caister Academic Press, U.K., 2007; pp, 61. www.about.qkport.com.
13. Anthony JF Griffiths, William M Gelbart, Jeffrey H Miller, Richard C Lewontin, Modern Genetic Analysis. W. H. Freeman, 1999, ISBN-10: 0-7167-3118-5.
14. Keen Eric C. et al., Novel "Superspreader" Bacteriophages Promote Horizontal Gene Transfer by Transformation, MBio., 2017; 8(1):e02115–16.
15. Martin C., The Application of Bacteriophage Tracer Techniques in South West Water. Water and Environment Journal, 1988; 2(6):638–642. www.about.qkport.com.
16. Mao C, Flynn CE, Hayhurst A, et al., Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci U S A., 2003; 100(12):6946–51.
17. Lee BY, Zhang J, Zueger C, et al., Virus-based piezoelectric energy generation. Nat Nanotechnol, 2012; 7(6):351–6.
18. Murugesan M, Abbineni G, Nimmo SL, et al., Virus-based photo-responsive nanowires formed by linking site-directed mutagenesis and chemical reaction, Sci Rep., 2013; 3:1820. www.f1000research.com.
19. Lee Y, Kim J, Yun DS, et al., Virus-templated Au and Au/Pt Core/shell Nanowires and Their Electrocatalytic Activitives for Fuel Cell Applications. Energy Environ Sci., 2012; 5(8):8328–34. www.f1000research.com.
20. Nam KT, Kim D, Yoo PJ, et al., Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes, Science, 2006; 312(5775):885–8. 42.
21. Yoo SY, Chung W, Kim TH, et al., Facile patterning of genetically engineered M13 bacteriophage for directional growth of human fibroblast cells, Soft Matter, 2011; 7(2):363–8.
22. Kim J, Winfree E, Synthetic in vitro transcriptional oscillators. Mol Syst Biol., 2011; 7:465. www.f1000research.com.
23. Enyeart PJ, Chirieleison SM, Dao MN, et al., Generalized bacterial genome editing using mobile group II introns and Cre-lox, Mol Syst Biol., 2013; 9:685.
24. Esvelt KM, Carlson JC, Liu DR: A system for the continuous directed evolution of biomolecules, Nature, 2011; 472(7344):499–503.
25. Jason J. Gill1, Baixin Wang, Emily Sestak, Ryland Young, Kung-Hui Chu, Characterization of a Novel Tectivirus Phage Toil and Its Potential as an Agent for Biolipid Extraction, Scientific Reports, 2018; 8:1062.
26. Twort FW, An investigation on the nature of ultramicroscopic viruses, Lancet 1915; 186:1241-3.
27. Sulakvelidze Alexander, Zemphira Alavidze, AND J. Glenn Morris, JR., Bacteriophage Therapy, Antimicrobial Agents And Chemotherapy, 2001; 45(3):649–659.
28. Zaman, G., A. Smetsers, A. Kaan, J. Schoenmaters, R. Konings, Regulation of expression of the genome of bacteriophage M13: Gene V protein regulated translation of the mRNAs encoded by genes I, II, V and X, Biochimica et Biophysica Acta, 1991, 1089:183-192.
29. Young R, Bacteriophage lysis: mechanism and regulation. Microbiology and Molecular Biology Reviews, 1992; 56:430-481.
30. Marza J., J. Soothill, P. Boydell T. Collyns, Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients, Burns, 2006; 32:644-646.
31. Weber-Dabrowska, B., M. Mulczyk, A. Gorski, Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz), 2000; 48:547-551. www.pdfs.semanticscholar.org.
32. Kumari, S., K. Harjai, S. Chhibber, Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of Medical Microbiology, 2011; 60:205-210.
33. Yao J. D. C., and Moellering RC, Jr., Antimicrobial agents, 1995; p. 1474–1504. In P. R. Murray, E. J. Baron, M. A. P faller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
34. Ayalew N and Ejo M, Review on Bacteriophages and its Antimicrobial Uses. Am-Euras. J. Sci. Res., 2016, 11(3):199-208.
35. Smith H. W., Huggins MB, Successful treatment of experimental Escherichia coli infections in mice using phages: its general superiorityover antibiotics, J. Gen. Microbiol., 1982; 128:307–318.
36. Borysowski J.,Międzybrodzki R., and Górski A., Phage Therapy, Current Research and Applications, 2014; Pp.6.
37. Goodridge D., Designing phage therapeutics. Curr. Pharm Biotechnol., 2010; 11:15-27.
38. Elizabeth Kutter, Daniel De Vos, Guram Gvasalia, Zemphira Alavidze, Lasha Gogokhia, Sarah Kuhl and Stephen T. Abedon, Phage Therapy in Clinical Practice: Treatment of Human Infections. Current Pharmaceutical Biotechnology, 2010; 11:69-86.
39. Sakandelidze V.M., The combined use of specific phages and antibiotics in different infectious allergoses, Vrach. Delo, 1991; 3:60-63.
40. Matsuzaki S., M. Rashel J. Uchiyma T. Ujihara, et al., Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy, 2005; 11:211-219.
41. Casto A., Hurwitz A., Kou K., et al., Bacteriophages: The answer to antibiotic resistance? James Madison Undergraduate Research Journal, 2016; 3(1):36-41.
42. Viertel T. M., Ritter K., & Horz H., Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. Journal of Antimicrobial Chemotherapy, 2014; 69(9):2326-2336. www.commons.lib.jmu.edu.
43. Bikard D, Euler CW, Jiang W, et al., Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials, Nat Biotechnol., 2014; 32(11):1146–50. www.f1000research.com.
44. Ahmed K, Kaderbhai NN, Kaderbhai MA, Bacteriophage therapy revisited, African J Microbiol Res., 2012; 6:3366-3379. www.microbiology5.org.
45. Daria Vaisman, Studying anthrax in a Soviet-era lab – with Western funding, 2007. www.nytimes.com.
46. Carl R. Merril, Dean Scholl, Sankar L. Adhya, The prospect for bacteriophage therapy in Western medicine. Nature Reviews Drug Discovery, 2003; 2:489-97.
47. McVay CS, Velásquez M, Fralick JA, Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model, Antimicrob. Agents Chemother, 2007; 51(6):1934–8.
48. WBUR News, Scientists Engineer Viruses to Battle Bacteria, 2009; NPR 2018.
49. Vaiva Kazanavičiūtė, Audrius Misiūnas, Yuri Gleba et al., Plant-expressed bacteriophage lysins control pathogenic strains of Clostridium perfringens; Scientific Reports, 2018; 8:10589.
50. Qin Peng, Yihui Yuan, Characterization of a newly isolated phage infecting pathogenic Escherichia coli and analysis of its mosaic structural genes, Scientific Reports, 2018; 8:8086.
51. Li Ma, Sabrina I. Green, Barbara W. Trautner et al., Metals Enhance the Killing of Bacteria by Bacteriophage in Human Blood. Scientific Reports, 2018; 8:2326.
52. Sangjin Park, Soo Youn Jun, Chang-Hwan Kim et al., Characterization of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis, Scientific Reports, 2018; 8:18.
53. George V. Tetz, Kelly V. Ruggles, Hua Zhou, Adriana Heguy et al., Bacteriophages as potential new mammalian pathogens. Scientific Reports, 2017; 7:7043.
54. Pallavali RR, Degati VL, Lomada D, Reddy MC, Durbaka VRP, Isolation and in vitro evaluation of bacteriophages against MDR bacterial isolates from septic wound infections, PLoS ONE, 2017; 12(7):e0179245.
55. Hernández I, Bacteriophages against Serratia as Fish Spoilage Control Technology. Front. Microbiol., 2017; 8:449.
56. Duerkop BA, Huo W, Bhardwaj P, Palmer KL, Hooper LV, Molecular basis for lytic bacteriophage resistance in enterococci, mBio., 2016; 7(4):e01304-16.
57. Gundogdu A, Bolkvadze D, Kilic H, In vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains. Front. Microbiol., 2016; 7:1761.
58. Kusradze I, Karumidze N, Rigvava S, Dvalidze T et al., Characterization and Testing the Efﬁciency of Acinetobacter baumannii Phage vB-GEC_Ab-M-G7 as an Antibacterial Agent, Front. Microbiol., 2016; 7:1590.
59. Borysowski J, Weber-Dabrowska B, Górski A, Bacteriophage endolysins as a novel class of antibacterial agents. Experimental Biology and Medicine (Maywood, N.J.), 2006; 231(4):366–77. www.en.wikipedia.org.
60. Lee JH, Moore LD, Kumar S, Pritchard DG et al., Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells, Cancer Lett, 2010; 298(2):238-49.
61. Lisa O'Sullivan, Colin Buttimer, Olivia McAuliffe, Declan Bolton, Aidan Coffey, Bacteriophage-based tools: recent advances and novel applications, F1000Research, F1000Research, 2016; 5(F1000 Faculty Rev):2782.
62. OJain P, Hartman TE, Eisenberg N, et al., 2012, fGFP10, a high-intensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples, J Clin Microbiol, 50(4):1362–9• www.f1000research.com.
63. Hodyra K, DaÞbrowska K., Molecular and chemical engineering of bacteriophages for potential medical applications, Arch Immunol Ther Exp, 2015; 63:117–127.
64. Clark JR, March JB, Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends in Biotechnol, 2006; 24: 212-18. www.microbiology5.org.
65. Vaks L, Benhar I., In vivo characteristics of targeted drug-carrying ﬁlamentous bacteriophage nanomedicines, J. Nanobiotechnology, 2011; 9:58.
66. Yacoby I, Bar H, Benhar I., Targeted drug-carrying bacteriophages as antibacterial nanomedicines, Antimicrob Agents Chemother, 2007; 51:2156–63.
67. Embleton ML, Nair SP, Heywood W et al., Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus, Antimicrob Agents Chemother, 2005; 49:3690–6. www.jac.oxfordjournals.org.
68. Wang T, D'Souza GG, Bedi D, Fagbohun OA, Potturi LP, Papahadjopoulos-Sternberg B, Petrenko VA, and Torchilin VP, Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond), 2010; 5(4):563–74.
69. Bar H, Yacoby I, Benhar I, Killing cancer cells by targeted drug-carrying phage nanomedicines, BMC Biotechnol, 2008, 8:37.
70. Hosoya H, Dobroff AS, Driessen WH, et al., Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release, Proc Natl Acad Sci U S A, 2016; 113(7):1877–82.
71. Brasino M, Cha JN, Real-time femtomolar detection of cancer biomarkers from photoconjugated antibody-phage constructs, 2016; Analyst.
72. Barry MA, Dower WJ, Johnston SA., To ward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide presenting phage libraries, Nat. Med, 1996; 2:299-305.
73. Qazi S, Miettinen HM, Wilkinson RA, et al., Programmed Self-Assembly of an Active P22-Cas9 Nanocarrier System, Mol Pharm, 2016; 13(3):1191–6.
74. Anders Lanzén, Addis Simachew, Amare Gessesse, Dominika Chmolowska, Inge Jonassen, Lise Øvreås, Surprising prokaryotic and eukaryotic diversity, community structure and biogeography of Ethiopian soda lakes, PLoS One, 2013; 8:e72577.
75. Leonardo Joaquim van Zyl, Shonisani Nemavhulani, James Cass, Donald Arthur Cowan, Marla Trindade, Three novel bacteriophages isolated from the East African Rift Valley soda lakes, Virology Journal, 2016; 13:204.
76. Getachew Belayneh, Azeb Tesfaye, Tsehaye Asmelash, Habtamu Taddle, Araya G. Therapeutic Potential Of Bacteriophage Isolated From Sewage For Multidrug Resistant Escherichia Coli Infection In Mice.
77. Kiros Ashenafi, Gashaw Tadele, Teshale Ayichew, Phage Therapy; A Review on the Biology and Therapeutic Application of Bacteriophage, RC Journal of Animal and Veterinary Sciences (AJAVS), 2016; 2(4):15-25.
78. Belay Mulugeta, Sisay Tesfaye, Wolde Tesfaye, Bacteriophages and phage products: Applications in medicine and biotechnological industries, and general concerns. Scientific Research and Essays, 2018; 13(6):55-70.
79. Paul M, Ethiopia Commemorates the First Antibiotics Awareness Week. WHO Country Office – Ethiopia, 2015. www.afro.who.int.
80. Feleke Moges, Mengistu Endris, Andargachew Mulu, Belay Tessema et al., The growing challenges of antibacterial drug resistance in Ethiopia, Journal of Global Antimicrobial Resistant, 2014; 2(3):148–154. www.jgaronline.com.
81. Endrias Z, Prevalence, Distribution And Antimicrobial Resistance profile Of Salmonella Isolated From Food Items And Personnel In Addis Ababa, Ethiopia [MSc Thesis], 2004. www.etd.aau.edu.et.
82. Liyuwork Tesfaw1, Biruhalem Taye, Sefinew Alemu, Haile Alemayehu, Zufan Sisay and Haileleul Negussie, Prevalence and antimicrobial resistance profile of Salmonella isolates from dairy products in Addis Ababa, Ethiopia; African Journal of Microbiology Research, 2013; 7(43):5046-5050.
83. Andrzej Górski, Ryszard Mi˛edzybrodzki, Malgorzata Lobocka et al., Phage Therapy: What Have We Learned? Viruses, 2018; 10:288.
84. Nagel T.E., Chan, B.K, De Vos D, El-shibiny A, Kang'ethe EK, Makumi A, Pirnay JP, The developing world urgently needs phages to combat pathogenic bacteria, Front. Microbiol, 2016; 7:882.
85. Coker, A. O., Isokpehi, R. D., Thomas, B. N., Amisu, K. O., Obi, C. L., Human campylobacterios is in developing countries, Emerg. Infect. Dis, 2002; 8:237–244.
86. Ethiopian Investment Commission, Investing in Ethiopia: The future pharmaceutical hub of Africa, 2018; Pp. 1-15.
87. Available online: https://www.phagesforglobalhealth.org/ (accessed on 16 July 2018).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).